EAS Abstracts 2015.Indd
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Lifestyle Drugs” for Men and Women
Development of “Lifestyle Drugs” for Men and Women Armin Schultz CRS - Clinical Research Services Mannheim GmbH AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Smart drugs, Quality-of-life drugs, Vanity drugs etc. Lifestyle? Lifestyle-Drugs? Active development? Discovery by chance? AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle A lifestyle is a characteristic bundle of behaviors that makes sense to both others and oneself in a given time and place, including social relations, consumption, entertainment, and dress. The behaviors and practices within lifestyles are a mixture of habits, conventional ways of doing things, and reasoned actions „Ein Lebensstil ist [...] der regelmäßig wiederkehrende Gesamtzusammenhang der Verhaltensweisen, Interaktionen, Meinungen, Wissensbestände und bewertenden Einstellungen eines Menschen“ (Hradil 2005: 46) Different definitions in social sciences, philosophy, psychology or medicine AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle Many “subdivisions” LOHAS: “Lifestyles of Health and Sustainability“ LOVOS: “Lifestyles of Voluntary Simplicity“ SLOHAS: “Slow Lifestyles of Happiness and Sustainability” PARKOS: “Partizipative Konsumenten“ ……. ……. ……. AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Lifestyle drug is an imprecise term commonly applied to medications which treat non-life threatening and non-painful conditions such as baldness, impotence, wrinkles, or acne, without any medical relevance at all or only minor medical relevance relative to others. Desire for increase of personal well-being and quality of life It is sometimes intended as a pejorative, bearing the implication that the scarce medical research resources allocated to develop such drugs were spent frivolously when they could have been better spent researching cures for more serious medical conditions. -
ECO-Ssls for Pahs
Ecological Soil Screening Levels for Polycyclic Aromatic Hydrocarbons (PAHs) Interim Final OSWER Directive 9285.7-78 U.S. Environmental Protection Agency Office of Solid Waste and Emergency Response 1200 Pennsylvania Avenue, N.W. Washington, DC 20460 June 2007 This page intentionally left blank TABLE OF CONTENTS 1.0 INTRODUCTION .......................................................1 2.0 SUMMARY OF ECO-SSLs FOR PAHs......................................1 3.0 ECO-SSL FOR TERRESTRIAL PLANTS....................................4 5.0 ECO-SSL FOR AVIAN WILDLIFE.........................................8 6.0 ECO-SSL FOR MAMMALIAN WILDLIFE..................................8 6.1 Mammalian TRV ...................................................8 6.2 Estimation of Dose and Calculation of the Eco-SSL ........................9 7.0 REFERENCES .........................................................16 7.1 General PAH References ............................................16 7.2 References Used for Derivation of Plant and Soil Invertebrate Eco-SSLs ......17 7.3 References Rejected for Use in Derivation of Plant and Soil Invertebrate Eco-SSLs ...............................................................18 7.4 References Used in Derivation of Wildlife TRVs .........................25 7.5 References Rejected for Use in Derivation of Wildlife TRV ................28 i LIST OF TABLES Table 2.1 PAH Eco-SSLs (mg/kg dry weight in soil) ..............................4 Table 3.1 Plant Toxicity Data - PAHs ..........................................5 Table 4.1 -
OECD Environment Health and Safety Publications Series on Testing and Assessment No
OECD Environment Health and Safety Publications Series on Testing and Assessment No. 21 Detailed Review Paper Appraisal of Test Methods for Sex Hormone Disrupting Chemicals Environment Directorate ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT Paris May 2001 1 Also Published in the Series Testing and Assessment: No. 1, Guidance Document for the Development of OECD Guidelines for Testing of Chemicals (1993; reformatted 1995) No. 2, Detailed Review Paper on Biodegradability Testing (1995) No. 3, Guidance Document for Aquatic Effects Assessment (1995) No. 4, Report of the OECD Workshop on Environmental Hazard/Risk Assessment (1995) No. 5, Report of the SETAC/OECD Workshop on Avian Toxicity Testing (1996) No. 6, Report of the Final Ring-test of the Daphnia magna Reproduction Test (1997) No. 7, Guidance Document on Direct Phototransformation of Chemicals in Water (1997) No. 8, Report of the OECD Workshop on Sharing Information about New Industrial Chemicals Assessment (1997) No. 9 Guidance Document for the Conduct of Studies of Occupational Exposure to Pesticides During Agricultural Application (1997) No. 10, Report of the OECD Workshop on Statistical Analysis of Aquatic Toxicity Data (1998) No. 11, Detailed Review Paper on Aquatic Testing Methods for Pesticides and industrial Chemicals (1998) No. 12, Detailed Review Document on Classification Systems for Germ Cell Mutagenicity in OECD Member Countries (1998) No. 13, Detailed Review Document on Classification Systems for Sensitising Substances in OECD Member Countries 1998) No. 14, Detailed Review Document on Classification Systems for Eye Irritation/Corrosion in OECD Member Countries (1998) No. 15, Detailed Review Document on Classification Systems for Reproductive Toxicity in OECD Member Countries (1998) No. -
Diagnostic and Prognostic Advances in Pediatric Mild Traumatic Brain Injury
Diagnostic and Prognostic Advances in Pediatric Mild Traumatic Brain Injury Lynn Babcock, MD, MS Division of Pediatric Emergency Medicine CME Disclosure Statement Lynn Babcock, MD, MS • I have no relevant financial relationships with the manufacturer(s) of any commercial product(s) and/or provider of commercial services discussed in this CME activity. • I do not intend to discuss an unapproved or investigative use of a commercial product/device in my presentation. Learning Objectives 1. Implement current diagnostic and prognostic methods for children with mild TBI. 2. Understand how serum biomarkers aid in the diagnosis and prognosis of children with mild TBI. 3. Appreciate advanced neuroimaging as a diagnostic and prognostic tool for children with mild TBI. Case 9 year old boy is playing hockey. Helmeted. Is chasing after the puck, gets tripped (of course accidently) and then gets pile driven into the boards by a much larger 10 year old. He appears unresponsive for a about 1 minute, then he starts to cry. He is unable to get up, and then is helped off the ice. He is dazed and confused for about 5 minutes. His parents bring him into ED. Parents ask: Does he have a brain injury? When can he go back into the game? Primary Injury • “Focal” injuries • “Diffuse” injuries – Direct mechanical damage – Rotational forces critical – Impact – Acceleration, deceleration – Acceleration, deceleration – Results: – Results: • Axonal stretch à axotomy • Coup/counter coup • Primary axotomy • Hemorrhage/infarction • Microhemorrhages • Rapid oncotic injury -
Effect of Surfactant–Bile Interactions on the Solubility of Hydrophobic
Article Cite This: Mol. Pharmaceutics 2018, 15, 5741−5753 pubs.acs.org/molecularpharmaceutics Effect of Surfactant−Bile Interactions on the Solubility of Hydrophobic Drugs in Biorelevant Dissolution Media Zahari Vinarov,*,† Vladimir Katev,† Nikola Burdzhiev,‡ Slavka Tcholakova,† and Nikolai Denkov† † Department of Chemical and Pharmaceutical Engineering, Faculty of Chemistry and Pharmacy, Sofia University, 1164 Sofia, Bulgaria ‡ Department of Organic Chemistry and Pharmacognosy, Faculty of Chemistry and Pharmacy, Sofia University, 1164 Sofia, Bulgaria *S Supporting Information ABSTRACT: Biorelevant dissolution media (BDM) methods are commonly employed to investigate the oral absorption of poorly water-soluble drugs. Despite the significant progress in this area, the effect of commonly employed pharmaceutical excipients, such as surfactants, on the solubility of drugs in BDM has not been characterized in detail. The aim of this study is to clarify the impact of surfactant−bile interactions on drug solubility by using a set of 12 surfactants, 3 model hydrophobic drugs (fenofibrate, danazol, and progesterone) and two types of BDM (porcine bile extract and sodium taurodeoxycholate). Drug precipitation and sharp nonlinear decrease in the solubility of all studied drugs is observed when drug-loaded ionic surfactant micelles are introduced in solutions of both BDM, whereas the drugs remain solubilized in the mixtures of nonionic polysorbate surfactants + BDM. One-dimensional and diffusion-ordered 1H NMR spectroscopy show that mixed bile salt + surfactant micelles with low drug solubilization capacity are formed for the ionic surfactants. On the other hand, separate surfactant-rich and bile salt-rich micelles coexist in the nonionic polysorbate surfactant + bile salt mixtures, explaining the better drug solubility in these systems. -
Drugs Influencing Cognitive Function
Indian J Physiol Phannacol 1994; 38(4) : 241-251 RE\llEW ARTICLE DRUGS INFLUENCING COGNITIVE FUNCTION ALICE KURUYILLA* AND YASUNDARA DEYI Department ofPharmacology. Christian Medical College. Vellore - 632 002 DRUGS INFLUENCING COGNITIVE FUNCTION cerebrovascular disorders with dementias and reversible dementias. Drugs can inOuence cognitive function in several different ways. The cognitrve enhancers or nootropics Primary degenerative disorders include the have become a major issue in drug development during subgroups senile dementia of the Alzheimer's type the last decade. Nootropics arc defined as drugs that (SDAT), Alzheimer's disease, Picks disease and generally increase neuron metabolic activity, improve Huntington's chorea (4). Alzheimer's disease usually cognitive and ,'igilance level and are said to have occurs in individuals past 70 years old and appears to antidemcntia effect (I). These drugs are essential for be in part genetically determin'd (5). the treatment of geriatric disorders like Alzheimer's which have become one of the major problems socially Pathophysiology oj Alzheimer's disease : and medically. Considerable evidence has been gathered Extensive research in the recent years has made major in the last decade to support the observation that advances in understanding the pathogenesis of children with epilepsy have morc learning difficulties Alzheimer's disease (6). The hallmark lesions of than age matched controls (2, 3). Anti-epileptic drugs Alzheimer's disease are neuritic plaques and are useful in controlling the frequency and duration of neurofibrillary tangles. Two amyloid proteins seizures. These drugs can also be the source of side accumulate in Alzheimer's disease, these arc beta effects including cognitive impairment. -
(12) Patent Application Publication (10) Pub. No.: US 2008/0299054 A1 Chandar Et Al
US 20080299054A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0299054 A1 Chandar et al. (43) Pub. Date: Dec. 4, 2008 (54) PERSONAL CARE COMPOSITIONS WITH Publication Classification ENHANCED FRAGRANCE DELVERY (51) Int. Cl. (75) Inventors: Prem Chandar, Closter, NJ (US); A6IR 8/34 (2006.01) Lin Yang, Woodbridge, CT (US) A6II 3/14 (2006.01) A6II 3/17 (2006.01) Correspondence Address: UNILEVER PATENT GROUP (52) U.S. Cl. .............. 424/54; 424/59: 424/65; 424/70.1; 800 SYLVANAVENUE, AG West S. Wing 514/588 ENGLEWOOD CLIFFS, NJ 07632-3100 (US) (57) ABSTRACT (73) Assignee: CONOPCO, INC., d/b/a UNILEVER, Englewood Cliffs, NJ A personal care product is provided which includes a fra (US) grance, a Substituted urea and a quaternary ammonium salt. The Substituted urea and quaternary ammonium salt operate (21) Appl. No.: 11/755,009 together as a scent boosting system to enhance Volatilization offragrance components upon the personal care composition (22) Filed: May 30, 2007 being first applied to human skin or hair. US 2008/0299054 A1 Dec. 4, 2008 PERSONAL CARE COMPOSITIONS WITH structure AB, wherein A is a cationic charged compo ENHANCED FRAGRANCE DELVERY nent of the salt AB, B is an anionic charged component of the salt AB, and BACKGROUND OF THE INVENTION 0013 A has a single quaternized nitrogen atom, at least two hydroxy groups and a molecular weight no 0001 1. Field of the Invention higher than about 250. 0002 The invention concerns personal care compositions which upon application to a human body Surface quickly release fragrance components thereby improving aesthetics DETAILED DESCRIPTION OF THE INVENTION of these compositions. -
Cognitive Enhancing Agents: Current Status in the Treatment of Alzheimer's Disease
LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES REVIEW ARTICLE Cognitive Enhancing Agents: Current Status in the Treatment of Alzheimer's Disease Cheryl Waters ABSTRACT: Extensive recent literature on drugs used to enhance cognitive functioning, reflects the growing social problem of dementia. Many clinical trials have been undertaken with variable success. In most cases the disorder stud ied has been Alzheimer's disease. The pharmacological approach has been designed to rectify the presumed patho physiological processes characteristic of the condition. Agents tested include cerebral vasodilators, cerebral metabolic enhancers, nootropics, psychostimulants, neuropeptides and neurotransmitters with a special emphasis on drugs used to enhance cholinergic function. Ethical and practical issues concerning clinical drug trials in dementia will be discussed. RESUME: Stimulation cognitive medicamenteuse: etat de la question dans le traitement de la maladie d'Alzheimer La multiplicity des publications recentes sur les medicaments utilises pour stimuler le fonctionnement cognitif est le reflet du probl&me social sans cesse croissant de la d6mence. Plusieurs essais cliniques ont ete tentes avec des resultats variables. Dans la plupart des cas, la maladie etudiee etait la maladie d'Alzheimer. L'approche pharmacologique a ete con^ue pour corriger les processus physiopathologiques caracteristiques de la maladie. Les agents etudies incluent des vasodilatateurs cerebraux, des stimulants metaboliques cerebraux, des agents nootropes, des agents neurotropes, -
Pharmaceutical Appendix to the Tariff Schedule 2
Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9 -
Biodegradation of Linear Alkylbenzene Sulfonates
BIODEGRADATION OF LINEAR ALKYLBENZENE SULFONATES Applicable to these current Stepan products: BIO-SOFT® D-40 BIO-SOFT® N-300 BIO-SOFT® N-411 BIO-SOFT® S-101 BIO-SOFT® S-101 LS BIO-SOFT® S-111 H BIO-SOFT® S-118 BIO-SOFT® S-120 NACCONOL® 40G NACCONOL® 90G POLYSTEP® A-15 POLYSTEP® A-15-30K STEPWET® DF-90 STEPANTAN® DT-60 BIO-SOFT® D-62 LT BIO-SOFT® L2P-123 POLYSTEP®A-15F Applicable to these inactive Stepan products: BIO-SOFT® D-53 BIO-SOFT® S-100 BIO-SOFT® S-130 POLYSTEP® A-13 POLYSTEP® A-4 POLYSTEP® A-7 STEPANTAN® DS-40 Biodegradation Information: Since their introduction in 1965, linear alkylbenzene sulfonates (LAS) have been used throughout the world as the main anionic surfactant in both household and industrial detergent products. As a result of their wide spread use, the biodegradation characteristics of LAS have been studied thoroughly under both laboratory and environmental conditions. Laboratory tests typically show that LAS will undergo rapid primary and ultimate biodegradation. Due to its favorable biodegradation characteristics, LAS is presently listed as a recommended control substance in the OECD "Readily Biodegradability: Closed Bottle Test". OECD Modified Sturm testing of a LAS product, BIO-SOFT® S-100, showed this product to be readily biodegradable. Primary biodegradation, which can reach 100% in 3 days, involves oxidation of the carbon atoms at the alkyl side chain to form transient, low toxicity sulfophenyl carboxylate intermediates. This is followed by complete breakdown characterized by cleavage of the aromatic ring and total mineralization to carbon dioxide, water and inorganic sulfonates. -
(12) United States Patent (10) Patent No.: US 8.470,756 B2 O’Brien (45) Date of Patent: Jun
USOO8470756B2 (12) United States Patent (10) Patent No.: US 8.470,756 B2 O’Brien (45) Date of Patent: Jun. 25, 2013 (54) ECO-FRIENDLY LAUNDRY 6,995,127 B1 2/2006 Smith et al. PRETREATMENT COMPOSITIONS 7,077,870 B2 7/2006 Findlay et al. 7,250,174 B2 7/2007 Lee et al. 7,452,917 B2 11/2008 Baumoeller et al. (75) Inventor: Jeanne A. O’Brien, Racine, WI (US) 7,608,573 B1 10/2009 Scheuing et al. 7,618.931 B1 1 1/2009 Scheuing et al. (73) Assignee: S.C. Johnson & Son, Inc., Racine, WI 2002/0028755 A1* 3/2002 Van Dijk et al. .............. 510,392 2003, OO13629 A1 1/2003 Kischkelet al. (US) 2003/0027736 A1 2/2003 Raths et al. 2003/O122101 A1 7/2003 Prozzo et al. (*) Notice: Subject to any disclaimer, the term of this 2006.0053566 A1 3/2006 Prozzo et al. patent is extended or adjusted under 35 2006/010.5937 A1 5, 2006 Duran U.S.C. 154(b) by 312 days. 2007, OO 10416 A1 1, 2007 Wu et al. 2007/0179074 A1 8, 2007 Souter et al. 2007/O1968.98 A1 8, 2007 Nielsen et al. (21) Appl. No.: 12/405,862 2007/0275021 A1 11/2007 Lee et al. 2008/0000032 A1 1/2008 Wieprecht et al. (22) Filed: Mar 17, 2009 2008.0171683 A1 7/2008 Johnson et al. 2008/O187958 A1 8, 2008 Nielsen et al. (65) Prior Publication Data 2008. O194453 A1 8/2008 Lang 2009.0054294 A1 2/2009 Theiler US 2010/O144580 A1 Jun. -
Personal Care Compositions with Silicones And
(19) & (11) EP 1 804 922 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61Q 19/00 (2006.01) A61Q 1/02 (2006.01) 13.02.2008 Bulletin 2008/07 A61Q 19/10 (2006.01) A61Q 5/02 (2006.01) A61Q 5/12 (2006.01) A61Q 15/00 (2006.01) (2006.01) (2006.01) (21) Application number: 05797352.1 A61Q 11/00 A61K 8/896 A61K 8/891 (2006.01) A61K 8/58 (2006.01) A61K 8/898 (2006.01) A61K 8/41 (2006.01) (22) Date of filing: 24.10.2005 (86) International application number: PCT/EP2005/011416 (87) International publication number: WO 2006/045583 (04.05.2006 Gazette 2006/18) (54) PERSONAL CARE COMPOSITIONS WITH SILICONES AND DIHYDROXYPROPYL TRIALKYL AMMONIUM SALTS KÖRPERPFLEGEZUSAMMENSETZUNGEN MIT SILIKONEN UND DIHYDROXYPROPYL- TRIALKYL-AMMONIUMSALZEN COMPOSITIONS DE SOINS PERSONNELS COMPRENANT DES COMPOSES SILICONES ET DES SELS DE DIHYDROXYPROPYL TRIALKYL AMMONIUM (84) Designated Contracting States: • MINER, Philip E. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Unilever Home&Personal Care USA HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI Trumbull, CT 06611 (US) SK TR • BARROW, Stephen Unilever Home&Personal Care USA (30) Priority: 25.10.2004 US 972483 Trumbull, CT 06611 (US) 08.09.2005 US 222189 • CHANDAR, Prem Unilever Home&Personal Care USA (43) Date of publication of application: Trumbull, CT 06611 (US) 11.07.2007 Bulletin 2007/28 • MCMANUS, Richard Unilever Home&Personal Care USA (73) Proprietors: Trumbull, CT 06611 (US) • UNILEVER PLC • HARICHIAN, Bijan London, Greater London EC4P 4BQ (GB) Unilever T.